Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Mar 25, 2015 at 9:15 AM EDT

Major Biotech Is So-So for Short Sellers

The March 13 short interest data in top biotechs have been compared with the end of February figures, and across…

Lee Jackson | Mar 25, 2015 at 8:45 AM EDT

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

Deutsche Bank says that investors have misread the current instances floating around two leading biotech stocks, and they both should…

Chris Lange | Mar 24, 2015 at 9:55 AM EDT

Can MEI Pharma Survive?

After MEI Pharma cratered in the wake of disappointing results from one of its studies, analysts are making their calls…

Jon C. Ogg | Mar 23, 2015 at 10:35 AM EDT

The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%

ThinkstockThe multiyear run in major biotech stocks has not let up in 2015. Most of the large and mid-cap stocks…

Lee Jackson | Mar 23, 2015 at 9:05 AM EDT

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

A new research report from the technical team at RBC cites Bristol-Myers Squibb, Eli Lilly, Mylan and Perrigo as stocks…

Chris Lange | Mar 20, 2015 at 9:50 AM EDT

Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec

Friday morning, Biogen Idec announced positive results related to its Alzheimer's study. Any real Alzheimer's drug certainly would make the…

Chris Lange | Mar 20, 2015 at 9:20 AM EDT

How Large Is Prothena’s Market Opportunity?

Prothena has announced positive results from a Phase 1 study of a monoclonal antibody for the potential treatment of Parkinson's…

Chris Lange | Mar 19, 2015 at 10:35 AM EDT

How the Tekmira Secondary Offering Could Help the Company

Tekmira Pharmaceuticals, one of the top names in the Ebola drug arena, is now about to raise a significant amount…

Chris Lange | Mar 18, 2015 at 2:10 PM EDT

How the Weaker Euro Is Impacting Biotech Earnings

Wells Fargo released a report Wednesday that considers the future of major biotech companies in relation to the weak euro.

Chris Lange | Mar 16, 2015 at 9:10 AM EDT

As Valeant Ups Salix Buyout, Will Endo Come Back?

Salix Pharmaceuticals and Valeant Pharmaceuticals have announced that they had entered into an agreement on their plan to merge based…

Lee Jackson | Mar 16, 2015 at 8:15 AM EDT

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

One thing that can always drive a biotech stock higher is positive clinical data, and this week some big-time biotech…

Chris Lange | Mar 13, 2015 at 12:20 PM EDT

Par Pharma Files for IPO

Par Pharmaceutical Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering.

Chris Lange | Mar 11, 2015 at 2:39 PM EDT

Salix Now Has 2 Merger Dance Partners

A new bid from Endo International has made the merger situation around Salix Pharmaceuticals much more complicated.

Chris Lange | Mar 11, 2015 at 1:45 PM EDT

The Gamble That Did Not Pay Off

Zogenix has announced an agreement for the sale of its Zohydro ER (hydrocodone bitartrate) business to Pernix for $100 million.

Lee Jackson | Mar 11, 2015 at 9:40 AM EDT

4 Top Pharmaceutical Stocks to Buy for Market Safety

A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to…

1 … 267 268 269 270 271 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Major Biotech Is So-So for Short Sellers

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

Can MEI Pharma Survive?

The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec

How Large Is Prothena’s Market Opportunity?

How the Tekmira Secondary Offering Could Help the Company

How the Weaker Euro Is Impacting Biotech Earnings

As Valeant Ups Salix Buyout, Will Endo Come Back?

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

Par Pharma Files for IPO

Salix Now Has 2 Merger Dance Partners

The Gamble That Did Not Pay Off

4 Top Pharmaceutical Stocks to Buy for Market Safety

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

KLA Is Gaining Share as AI Chip Complexity Drives Up Yield Costs

Magna Stock Craters 10% as Strong Q1 Fails to Lift Full-Year Outlook

Broadcom, Qualcomm, or TSMC: Why One AI Chip Stock Won Decisively in April

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

KLA Is Gaining Share as AI Chip Complexity Drives Up Yield Costs

Magna Stock Craters 10% as Strong Q1 Fails to Lift Full-Year Outlook

Health and Healthcare Articles

All Health and Healthcare Articles

Major Biotech Is So-So for Short Sellers

Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks

Can MEI Pharma Survive?

The Top 5 Biotech Stocks of 2015 — Average Gains So Far Over 200%

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

Alzheimer’s Drug Could Be Instant Blockbuster for Biogen Idec

How Large Is Prothena’s Market Opportunity?

How the Tekmira Secondary Offering Could Help the Company

How the Weaker Euro Is Impacting Biotech Earnings

As Valeant Ups Salix Buyout, Will Endo Come Back?

3 Leading Biotech Stocks Releasing Potential Catalyst Data This Week

Par Pharma Files for IPO

Salix Now Has 2 Merger Dance Partners

The Gamble That Did Not Pay Off

4 Top Pharmaceutical Stocks to Buy for Market Safety

Live: onsemi Q1 Earnings Tonight. Can the Stock Continue Its 90% YTD Rally?

Live: Will Palantir Beat Q1 Earnings Tonight After Market Close?

KLA Is Gaining Share as AI Chip Complexity Drives Up Yield Costs

Magna Stock Craters 10% as Strong Q1 Fails to Lift Full-Year Outlook

Broadcom, Qualcomm, or TSMC: Why One AI Chip Stock Won Decisively in April

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how